Dibotermin Alfa
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Dibotermin alfa: From Bone Repair to Esotropia
One-Sentence Summary
Dibotermin alfa is a recombinant human bone morphogenetic protein-2 (rhBMP-2) belonging to the TGF-β superfamily, originally used to promote bone formation in spinal fusion surgery and fracture repair. The TxGNN model predicts it may be effective for Esotropia (convergent strabismus), with 0 clinical trials and 0 publications currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Bone repair / Spinal fusion (known use; no Taiwan regulatory data on file) |
| Predicted New Indication | Esotropia |
| TxGNN Prediction Score | 99.97% |
| Evidence Level | L5 |
| EU Market Status | ✗ Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available from the provided evidence pack. Based on known pharmaceutical information, Dibotermin alfa is a recombinant form of human BMP-2, a potent osteoinductive growth factor. It acts through SMAD signalling pathways to drive mesenchymal stem cell differentiation into osteoblasts and chondrocytes, making it a cornerstone of surgical bone grafting applications such as anterior lumbar interbody fusion and acute open tibial fracture repair.
Esotropia is a form of strabismus defined by inward deviation of the eye, arising from neuromuscular imbalance or anatomical malalignment of the extraocular muscles. It is managed with optical correction, amblyopia patching, botulinum toxin injection, or corrective surgery — none of which involve osteogenic signalling.
There is no established pharmacological rationale linking BMP-2’s bone induction pathway to extraocular muscle tone, ocular alignment, or the neural circuitry governing conjugate gaze. The mechanistic review within this evidence pack concludes that no viable drug-disease hypothesis exists. This prediction is most likely an artefact of graph-based knowledge propagation in the TxGNN model rather than a biologically grounded repurposing candidate.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
EU Market Information
Dibotermin alfa currently holds no EU marketing authorisations on record (0 licences). The product is not available on the EU market.
Safety Considerations
Please refer to the SmPC for safety information.
Note: Taiwan TFDA prescribing information (warnings, contraindications, and drug interactions) was not available at the time of this report. This constitutes a blocking data gap (DG001) for formal safety screening.
Conclusion and Next Steps
Decision: Hold
Rationale: All ten TxGNN-predicted indications for Dibotermin alfa — including esotropia, multiple breast cancer subtypes, oesophageal malformation, multifocal choroiditis, aortic coarctation, and anaemia of prematurity — carry L5 evidence with zero supporting clinical trials or relevant literature, and each has been assessed as mechanistically implausible given BMP-2’s osteogenic mode of action. No viable repurposing pathway is identified at this stage.
To proceed, the following is needed:
- MOA confirmation (DG002): Retrieve full DrugBank pharmacology entry to confirm mechanism, targets, and known off-target effects before any secondary indication is re-evaluated.
- Safety data (DG001): Obtain Taiwan TFDA prescribing information (SmPC equivalent) to complete the mandatory S1 safety screening; this is currently a blocking data gap.
- Preclinical hypothesis generation: Any future repurposing attempt would first require identification of a plausible biological hypothesis — particularly for the cardiovascular or immunological predictions — followed by wet-lab proof-of-concept before clinical consideration.
- Reassessment trigger: If new BMP-2 mechanistic literature emerges (e.g., anti-tumour activity in specific cancer subtypes or immunomodulatory effects in ocular inflammation), the rank 2–8 candidates (HER2+ breast carcinoma, multifocal choroiditis) may warrant re-scoring at that time.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.